New microscopy method provides unprecedented look at amyloid protein structure
A new technique developed in the lab of Matthew Lew at the McKelvey School of Engineering at Washington University in St. Louis measures the orientation of single molecules. It is enabling, for the first time, optical microscopy to reveal nanoscale details about the structures of these problematic proteins.
The power of tea
A team of engineers at Washington University in St. Louis and their German collaborators say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders.
Antidepressant may slow Alzheimer’s disease
Antidepressants can reduce production of the main ingredient of Alzheimer’s brain plaques, according to new research at Washington University School of Medicine in St. Louis and the University of Pennsylvania. The plaques are highlighted in red in this image of a mouse’s brain.
Trial to test prevention of Alzheimer’s has begun
Finding ways to diagnose and
treat Alzheimer’s disease has frustrated scientists and clinicians for decades. But now the battle has reached a potentially significant milestone: the launch of the first clinical trials to test whether giving new drug treatments before dementia can prevent Alzheimer’s. Shown are School of Medicine MDs and Alzheimer’s researchers Randall Bateman (left) and John C. Morris.
Receptor may aid spread of Alzheimer’s and Parkinson’s in brain
School of Medicine
scientists have found a way that corrupted, disease-causing proteins
spread in the brain, potentially contributing to Alzheimer’s disease,
Parkinson’s disease and other brain-damaging disorders. Pictured are clumps of corrupted tau protein outside a nerve cell, as seen through an electron micrograph.
New perspective needed for role of major Alzheimer’s gene
Scientists’ picture of how a gene strongly linked to
Alzheimer’s disease harms the brain may have to be revised, researchers
at the School of Medicine have found. Washington University’s David M. Holtzman, MD, says leading researchers recently agreed that targeting this gene is a promising approach for gaining a better understanding of and improving treatments for the disease.
First detailed timeline established for brain’s descent into Alzheimer’s
Scientists have assembled the most detailed chronology
to date of the human brain’s long, slow slide into full-blown
Alzheimer’s disease. Through an international research partnership known as
the Dominantly Inherited Alzheimer’s Network (DIAN), scientists at
Washington University and elsewhere evaluated pre-symptomatic markers of Alzheimer’s disease in subjects from
families genetically predisposed to develop the disorder.
Marker for Alzheimer’s disease rises during day, falls with sleep
A marker for Alzheimer’s disease rises and falls in the spinal fluid in a daily pattern that echoes the sleep cycle, researchers at Washington University School of Medicine in St. Louis have found. The pattern is strongest in healthy young people and reinforces a link between increased Alzheimer’s risk and inadequate sleep that had been discovered in animal models.
Malfunctioning protein contributes to Alzheimer’s plaques
Scientists at Washington University School of Medicine in St. Louis have found that a protein made by a key Alzheimer’s gene slows the brain’s ability to get rid of amyloid beta, the main ingredient of the amyloid plaques that characterize the devastating illness.
MRI scans reveal brain changes in people at genetic risk for Alzheimer’s
People with a known, high risk for Alzheimer’s disease develop abnormal brain function even before the appearance of telltale, amyloid plaques that are characteristic of Alzheimer’s disease, according to a new study from researchers at Washington University School of Medicine in St. Louis. The findings suggest that a gene variant affects brain function long before the brain begins accumulating the amyloid that will eventually lead to dementia.
View More Stories